OTCMKTS:ALPMY - Astellas Pharma Stock Price, Price Target & More

$14.59 -0.14 (-0.95 %)
(As of 04/20/2018 12:31 PM ET)
Previous Close$14.73
Today's Range$14.5863 - $14.6050
52-Week Range$11.82 - $15.34
Volume9,280 shs
Average Volume79,894 shs
Market Capitalization$30.41 billion
P/E Ratio17.50
Dividend Yield0.78%
Beta0.27

About Astellas Pharma (OTCMKTS:ALPMY)

Astellas Pharma logoAstellas Pharma Inc., a pharmaceutical company, manufactures, markets, and imports and exports pharmaceutical products worldwide. The company offers Prograf and Advagraf/Graceptor/ASTAGRAF XL/Prograf XL, an immunosuppressant used to suppress organ transplant rejection; Vesicare, a treatment for overactive bladder; Harnal/Omnic, a blocking agent to treat the functional symptoms of benign prostatic hyperplasia; and Funguard/MYCAMIN, a candin-type antifungal agent. It also provides Geninax, an oral new-type quinolone antibacterial agent; Celecox, an anti-inflammatory agent; Lipitor, a treatment for hypercholesterolemia; Micardis/Micombi/Micamlo, a treatment for hypertension; Gaster, a treatment for peptic ulcer and gastritis; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic agonist indicated for the treatment of overactive bladder; Eligard, a luteinizing hormone-releasing hormone agonist for the treatment of prostate cancer; XTANDI for the treatment of prostate cancer; and VESOMNI, a release tablet for the treatment of moderate to severe storage symptoms and voiding symptoms associated with benign prostatic hyperplasia in men who are not adequately responding to treatment with monotherapy. In addition, the company offers Symbicort for the treatment for adult bronchial asthma and chronic obstructive pulmonary disease; Bonoteo for the treatment for osteoporosis; Suglat for the treatment of type 2 diabetes; and Repatha for the treatment of hypercholesterolemia. Further, the company provides Lexiscan, a pharmacologic stress agent; Tarceva, a treatment for non-small cell lung cancer; CRESEMBA, a azole antifungal; and Dificlir, a novel treatment for CDI. Additionally, it is developing enzalutamide, gilteritinib, and degarelix for oncology indications. The company has a collaborative research partnership with Astellas Pharma Inc. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.

Receive ALPMY News and Ratings via Email

Sign-up to receive the latest news and ratings for ALPMY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:ALPMY
CUSIPN/A
Phone813-3244-3000

Debt

Debt-to-Equity Ratio0.03%
Current Ratio2.34%
Quick Ratio1.97%

Price-To-Earnings

Trailing P/E Ratio17.50
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$12.13 billion
Price / Sales2.49
Cash Flow$1.1949 per share
Price / Cash12.21
Book Value$5.27 per share
Price / Book2.77

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$1.95 billion
Net Margins14.70%
Return on Equity14.40%
Return on Assets10.12%

Miscellaneous

EmployeesN/A
Outstanding Shares2,068,820,000

How to Become a New Pot Stock Millionaire

Astellas Pharma (OTCMKTS:ALPMY) Frequently Asked Questions

What is Astellas Pharma's stock symbol?

Astellas Pharma trades on the OTCMKTS under the ticker symbol "ALPMY."

When did Astellas Pharma's stock split? How did Astellas Pharma's stock split work?

Astellas Pharma's stock split on Wednesday, April 2nd 2014. The 5-4 split was announced on Friday, March 14th 2014. The newly created shares were payable to shareholders after the closing bell on Tuesday, April 1st 2014. An investor that had 100 shares of Astellas Pharma stock prior to the split would have 125 shares after the split.

How were Astellas Pharma's earnings last quarter?

Astellas Pharma (OTCMKTS:ALPMY) released its quarterly earnings results on Thursday, July, 27th. The company reported $0.23 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.24 by $0.01. The business had revenue of $2.90 billion for the quarter. Astellas Pharma had a net margin of 14.70% and a return on equity of 14.40%. View Astellas Pharma's Earnings History.

When is Astellas Pharma's next earnings date?

Astellas Pharma is scheduled to release their next quarterly earnings announcement on Thursday, April, 26th 2018. View Earnings Estimates for Astellas Pharma.

Who are some of Astellas Pharma's key competitors?

Who are Astellas Pharma's key executives?

Astellas Pharma's management team includes the folowing people:
  • Mr. Kenji Yasukawa Ph.D., Pres, CEO & Director (Age 58)
  • Mr. Chikashi Takeda, Chief Financial Officer
  • Mr. Stephen Knowles, Sr. VP of Fin. & Information Technology
  • Mr. Percival Barretto-Ko, Sr. VP of International Operations
  • Mr. Fumiaki Sakurai, Chief Admin. Officer & Chief Ethics & Compliance Officer

Has Astellas Pharma been receiving favorable news coverage?

Headlines about ALPMY stock have trended somewhat positive on Friday, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Astellas Pharma earned a news sentiment score of 0.06 on Accern's scale. They also gave news stories about the company an impact score of 47.06 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

How do I buy shares of Astellas Pharma?

Shares of ALPMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Astellas Pharma's stock price today?

One share of ALPMY stock can currently be purchased for approximately $14.59.

How big of a company is Astellas Pharma?

Astellas Pharma has a market capitalization of $30.41 billion and generates $12.13 billion in revenue each year.

How can I contact Astellas Pharma?

Astellas Pharma's mailing address is 2-5-1 Nihonbashi-Honcho Chuo-Ku, Tokyo M0, 103-8411. The company can be reached via phone at 813-3244-3000.


MarketBeat Community Rating for Astellas Pharma (ALPMY)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  88 (Vote Outperform)
Underperform Votes:  57 (Vote Underperform)
Total Votes:  145
MarketBeat's community ratings are surveys of what our community members think about Astellas Pharma and other stocks. Vote "Outperform" if you believe ALPMY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALPMY will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Astellas Pharma (OTCMKTS:ALPMY) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AN/AN/A
Consensus Rating Score: N/AN/AN/AN/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Astellas Pharma (OTCMKTS:ALPMY) Consensus Price Target History

Price Target History for Astellas Pharma (OTCMKTS:ALPMY)

Astellas Pharma (OTCMKTS:ALPMY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
7/7/2016UBSInitiated CoverageBuyView Rating Details
(Data available from 4/20/2016 forward)

Earnings

Astellas Pharma (OTCMKTS:ALPMY) Earnings History and Estimates Chart

Earnings by Quarter for Astellas Pharma (OTCMKTS:ALPMY)

Astellas Pharma (OTCMKTS ALPMY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/26/2018        
10/31/2017Q2 2018$0.17$2.8597 billionViewN/AView Earnings Details
7/27/20176/30/2017$0.24$0.23$2.9031 billionViewN/AView Earnings Details
4/27/2017Q4 2017$0.17$2.6904 billionViewN/AView Earnings Details
1/30/2017Q3 2017$0.28$3.2443 billionViewN/AView Earnings Details
10/28/2016Q2 2017$0.22$3.0664 billionViewN/AView Earnings Details
7/28/2016Q1 2017$0.29$3.0904 billionViewN/AView Earnings Details
5/11/2016Q4 2016$0.12$2.6590 billionViewN/AView Earnings Details
1/29/2016Q3 2016$0.23$3.1010 billionViewN/AView Earnings Details
10/30/2015Q2 2016$0.22$2.8195 billionViewN/AView Earnings Details
7/31/2015Q1 2016$0.17$2.8318 billionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Astellas Pharma (OTCMKTS:ALPMY) Dividend Information

Astellas Pharma pays an annual dividend of $0.12 per share, with a dividend yield of 0.82%.
Annual Dividend:$0.12
Dividend Yield:0.82%
Payout Ratio:N/A
Dividend Payments by Quarter for Astellas Pharma (OTCMKTS:ALPMY)

Astellas Pharma (OTCMKTS:ALPMY) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Astellas Pharma (OTCMKTS ALPMY) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 0.20%
Insider Trading History for Astellas Pharma (OTCMKTS:ALPMY)

Astellas Pharma (OTCMKTS ALPMY) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Astellas Pharma (OTCMKTS ALPMY) News Headlines

Source:
DateHeadline
Why It's So Dang Hard to Value Biotech DealsWhy It's So Dang Hard to Value Biotech Deals
finance.yahoo.com - March 21 at 4:25 PM
Pfizer's Xtandi Label Expansion Filing Gets Priority ReviewPfizer's Xtandi Label Expansion Filing Gets Priority Review
finance.yahoo.com - March 20 at 4:20 PM
U.S. FDA Grants Priority Review for a Supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) in Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)U.S. FDA Grants Priority Review for a Supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) in Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)
finance.yahoo.com - March 19 at 4:21 PM
3 Things In Biotech, March 18: Exelixis Lives, Astellas Digs Deeper, Alexion Equivocates3 Things In Biotech, March 18: Exelixis Lives, Astellas Digs Deeper, Alexion Equivocates
seekingalpha.com - March 19 at 9:40 AM
How Did Merck’s Invanz and Cancidas Perform in 2017?How Did Merck’s Invanz and Cancidas Perform in 2017?
finance.yahoo.com - March 16 at 9:45 AM
3 Things In Biotech, March 12: Pfizer Passes, Voyager Regresses PD, New Astellas Approval3 Things In Biotech, March 12: Pfizer Passes, Voyager Regresses PD, New Astellas Approval
seekingalpha.com - March 13 at 9:48 AM
Astellas to Present New Oncology Data at the 2018 ASCO Genitourinary Cancers (GU) SymposiumAstellas to Present New Oncology Data at the 2018 ASCO Genitourinary Cancers (GU) Symposium
finance.yahoo.com - January 29 at 4:25 PM
Astellas Completes Acquisition of Mitobridge, Inc.Astellas Completes Acquisition of Mitobridge, Inc.
www.prnewswire.com - January 23 at 10:25 PM
2018 Could Be Hallmark Year For These Two Antifungal Companies2018 Could Be Hallmark Year For These Two Antifungal Companies
finance.yahoo.com - January 8 at 4:07 PM
Astellas Announces First Clinical Data from Phase I Study of Gilteritinib in Combination with Intensive Chemotherapy in Patients Newly Diagnosed with Acute Myeloid LeukemiaAstellas Announces First Clinical Data from Phase I Study of Gilteritinib in Combination with Intensive Chemotherapy in Patients Newly Diagnosed with Acute Myeloid Leukemia
finance.yahoo.com - December 11 at 4:01 PM
Astellas Acquires Mitobridge Under Existing CollaborationAstellas Acquires Mitobridge Under Existing Collaboration
www.prnewswire.com - November 30 at 7:34 PM
Astellas to Present New Data Exploring Gilteritinib in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients at the 2017 American Society of Hematology Annual Meeting (ASH)Astellas to Present New Data Exploring Gilteritinib in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients at the 2017 American Society of Hematology Annual Meeting (ASH)
finance.yahoo.com - November 28 at 11:37 AM
ETFs with exposure to Astellas Pharma, Inc. : November 27, 2017ETFs with exposure to Astellas Pharma, Inc. : November 27, 2017
finance.yahoo.com - November 27 at 3:27 PM
ETFs with exposure to Astellas Pharma, Inc. : November 16, 2017ETFs with exposure to Astellas Pharma, Inc. : November 16, 2017
finance.yahoo.com - November 16 at 4:01 PM
Astellas Pharma, Inc. :ALPMY-US: Earnings Analysis: Q2, 2018 By the Numbers : November 15, 2017Astellas Pharma, Inc. :ALPMY-US: Earnings Analysis: Q2, 2018 By the Numbers : November 15, 2017
finance.yahoo.com - November 16 at 11:03 AM
Astellas faces U.S. probe over patient assistance charity supportAstellas faces U.S. probe over patient assistance charity support
finance.yahoo.com - November 16 at 11:03 AM
Astellas and Seattle Genetics Initiate Phase 1b Trial of Enfortumab Vedotin in Combination with Immune Checkpoint Inhibitor Therapies in Locally Advanced or Metastatic Urothelial CancerAstellas and Seattle Genetics Initiate Phase 1b Trial of Enfortumab Vedotin in Combination with Immune Checkpoint Inhibitor Therapies in Locally Advanced or Metastatic Urothelial Cancer
finance.yahoo.com - November 8 at 6:02 PM
ETFs with exposure to Astellas Pharma, Inc. : November 2, 2017ETFs with exposure to Astellas Pharma, Inc. : November 2, 2017
finance.yahoo.com - November 2 at 4:13 PM
Astellas Pharma, Inc. : ALPMY-US: Dividend Analysis : September 30th, 2017 (record date) : By the numbers : October 23, 2017Astellas Pharma, Inc. : ALPMY-US: Dividend Analysis : September 30th, 2017 (record date) : By the numbers : October 23, 2017
finance.yahoo.com - October 23 at 4:51 PM
Astellas and Universal Cells, Inc. Announce a Collaboration Utilizing Universal Donor Cell TechnologyAstellas and Universal Cells, Inc. Announce a Collaboration Utilizing Universal Donor Cell Technology
finance.yahoo.com - October 19 at 9:24 PM
U.S. FDA Grants Fast Track Designation to Astellas for Development of Gilteritinib in Relapsed or Refractory Acute Myeloid LeukemiaU.S. FDA Grants Fast Track Designation to Astellas for Development of Gilteritinib in Relapsed or Refractory Acute Myeloid Leukemia
finance.yahoo.com - October 10 at 10:13 PM
Astellas and Seattle Genetics Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial CancerAstellas and Seattle Genetics Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer
finance.yahoo.com - October 10 at 5:10 PM
Astellas Pharma, Inc. : ALPMY-US: Dividend Analysis : March 30th, 2017 (record date) : By the numbers : October 6, 2017Astellas Pharma, Inc. : ALPMY-US: Dividend Analysis : March 30th, 2017 (record date) : By the numbers : October 6, 2017
finance.yahoo.com - October 6 at 4:02 PM
Pfizer, Astellas prostate cancer drug promising in late-stage trialPfizer, Astellas prostate cancer drug promising in late-stage trial
finance.yahoo.com - September 14 at 4:17 PM
Why Did Pfizer (PFE) Stock Pop Today?Why Did Pfizer (PFE) Stock Pop Today?
finance.yahoo.com - September 14 at 4:17 PM
FDA Accepts For Review Astellas SNDA For MirabegronFDA Accepts For Review Astellas' SNDA For Mirabegron
www.rttnews.com - September 13 at 4:51 PM
U.S. FDA Accepts for Review Astellas Supplemental New Drug Application for mirabegron for Use in Combination with solifenacin succinate 5 mg for the Treatment of Overactive BladderU.S. FDA Accepts for Review Astellas' Supplemental New Drug Application for mirabegron for Use in Combination with solifenacin succinate 5 mg for the Treatment of Overactive Bladder
finance.yahoo.com - September 13 at 2:07 AM
ETFs with exposure to Astellas Pharma, Inc. : August 28, 2017ETFs with exposure to Astellas Pharma, Inc. : August 28, 2017
finance.yahoo.com - August 28 at 8:54 PM
Dr. Reddys Labs Launches Cefixime For Oral Suspension, USP In USDr. Reddy's Labs Launches Cefixime For Oral Suspension, USP In US
www.rttnews.com - August 28 at 3:51 PM
First Patient Dosed in Phase 3 MORPHO Trial Evaluating Gilteritinib as Maintenance Therapy Following Hematopoietic Stem Cell Transplant in Patients with FLT3 Mutation-positive Acute Myeloid LeukemiaFirst Patient Dosed in Phase 3 MORPHO Trial Evaluating Gilteritinib as Maintenance Therapy Following Hematopoietic Stem Cell Transplant in Patients with FLT3 Mutation-positive Acute Myeloid Leukemia
finance.yahoo.com - August 23 at 8:36 AM
FDA Approves IRWDs Gout Drug, Its A Thumbs Up For ALXN In EU, CRME CrushedFDA Approves IRWD's Gout Drug, It's A Thumbs Up For ALXN In EU, CRME Crushed
www.rttnews.com - August 22 at 1:57 AM
Astellas Pharma, Inc. :ALPMY-US: Earnings Analysis: Q1, 2018 By the Numbers : August 21, 2017Astellas Pharma, Inc. :ALPMY-US: Earnings Analysis: Q1, 2018 By the Numbers : August 21, 2017
finance.yahoo.com - August 21 at 3:54 PM
ETFs with exposure to Astellas Pharma, Inc. : August 8, 2017ETFs with exposure to Astellas Pharma, Inc. : August 8, 2017
finance.yahoo.com - August 8 at 8:24 PM
Astellas FQ1 top line up 5%, earnings up 44%Astellas FQ1 top line up 5%, earnings up 44%
seekingalpha.com - July 29 at 3:34 PM
Astellas Pharma (ALPMY) Releases  Earnings Results, Misses Estimates By $0.01 EPSAstellas Pharma (ALPMY) Releases Earnings Results, Misses Estimates By $0.01 EPS
www.americanbankingnews.com - July 29 at 1:38 PM
Astellas Announces Wind-Down of Agensys Research OperationsAstellas Announces Wind-Down of Agensys Research Operations
finance.yahoo.com - July 26 at 8:54 PM
Astellas Pharma: FDA Grants Orphan-Drug Designation To Gilteritinib In AMLAstellas Pharma: FDA Grants Orphan-Drug Designation To Gilteritinib In AML
www.rttnews.com - July 20 at 10:14 PM
U.S. FDA Grants Orphan-Drug Designation to Astellas for Development of FLT3 Inhibitor Gilteritinib in Acute Myeloid LeukemiaU.S. FDA Grants Orphan-Drug Designation to Astellas for Development of FLT3 Inhibitor Gilteritinib in Acute Myeloid Leukemia
finance.yahoo.com - July 20 at 5:09 PM
ETFs with exposure to Astellas Pharma, Inc. : July 10, 2017ETFs with exposure to Astellas Pharma, Inc. : July 10, 2017
finance.yahoo.com - July 10 at 3:42 PM
CARA In Pain, ALKS Enlightened, FDA Expands Approved Use Of AMGNs VectibixCARA In Pain, ALKS Enlightened, FDA Expands Approved Use Of AMGN's Vectibix
www.rttnews.com - June 30 at 3:50 PM
Astellas bails on late-stage lung cancer candidate ASP8273Astellas bails on late-stage lung cancer candidate ASP8273
seekingalpha.com - May 11 at 3:44 PM
Astellas Pharma To Discontinue ASP8273 Treatment Arm In Late-stage SOLAR TrialAstellas Pharma To Discontinue ASP8273 Treatment Arm In Late-stage SOLAR Trial
www.rttnews.com - May 11 at 1:40 AM
Astellas to acquire Belgian drug discovery firm Ogeda for up to €800MAstellas to acquire Belgian drug discovery firm Ogeda for up to €800M
seekingalpha.com - April 3 at 8:43 PM
Astellas Pharma To Buy OgedaAstellas Pharma To Buy Ogeda
www.nasdaq.com - April 3 at 1:25 AM
Astellas and Affinivax Announce Worldwide Partnership for MAPS Vaccine targeting Pneumococcal DiseaseAstellas and Affinivax Announce Worldwide Partnership for MAPS Vaccine targeting Pneumococcal Disease
au.finance.yahoo.com - February 28 at 8:54 AM
Astellas Reports the First Nine Months Financial Results of FY2016Astellas Reports the First Nine Months Financial Results of FY2016
au.finance.yahoo.com - January 31 at 1:49 AM
Astellas and Ironwood Report Positive Top-Line Results from Phase III Linaclotide Trial for Patients with Chronic Constipation Conducted in JapanAstellas and Ironwood Report Positive Top-Line Results from Phase III Linaclotide Trial for Patients with Chronic Constipation Conducted in Japan
au.finance.yahoo.com - January 29 at 8:28 PM
4:16 pm Astellas Pharma and Pfizer (<a href="/q?s=pfe" name="pfe">PFE</a>) announce the Phase 4 PLATO study, evaluating the efficacy and safety of continued treatment with XTANDI, plus abiraterone acetate and prednisone as compared to treat4:16 pm Astellas Pharma and Pfizer (PFE) announce the Phase 4 PLATO study, evaluating the efficacy and safety of continued treatment with XTANDI, plus abiraterone acetate and prednisone as compared to treat
us.rd.yahoo.com - December 15 at 1:41 AM
Astellas Research & Development Meeting HighlightsAstellas Research & Development Meeting Highlights
au.finance.yahoo.com - December 8 at 2:06 AM
Should Biopharma Companies Buy Innovation?Should Biopharma Companies Buy Innovation?
www.fool.com - November 22 at 1:40 PM

SEC Filings

Astellas Pharma (OTCMKTS:ALPMY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Astellas Pharma (OTCMKTS ALPMY) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.